< Back to previous page

Patent

Method for determining the severity and prognosis of RSV infection

The present invention provides an in vitro method for determining the severity and/or prognosis of a respiratory syncytial virus (RSV) infection in a subject, based on the expression of one or more mucin genes in respiratory epithelial cells. The respiratory epithelial cells can be isolated from a biological sample of a subject, or they can be cultured in vitro and exposed to a biological sample of the subject.
Patent Publication Number: WO2021053238
Year filing: 2021
Year approval: 2022
Year publication: 2021
Status: Requested
Technology domains: Analysis of biological materials
Validated for IOF-key: Yes
Attributed to: Associatie Universiteit & Hogescholen Antwerpen